Rocket One Inc. (HOTH) Research

Rocket One, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in Hoboken, NJ.

Market snapshot

Symbol
HOTH
Price
$1.07
Day change
-2.73%
Market cap
$24.1M
P/E ratio
-1.46x
52-week range
0.4894-2.45
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Recent news

  • Why Hoth Therapeutics (HOTH) Stock Is Surging After Hours Today

    Hoth Therapeutics stock surged after announcing its Rocket One rebrand and new AI chip technology focus.

Peer companies

  • Aspire Biopharma Holdings, Inc. (ASBP)
  • BriaCell Therapeutics Corp. (BCTX)
  • Curis, Inc. (CRIS)
  • Daré Bioscience, Inc. (DARE)
  • Entero Therapeutics, Inc. (ENTO)
  • FibroBiologics, Inc. Common Stock (FBLG)
  • Lexaria Bioscience Corp. (LEXX)
  • Palisade Bio, Inc. (PALI)

Open Rocket One Inc. (HOTH) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.